Refractory Schizophrenia
8
2
2
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Deep Brain Stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the Treatment of Refractory Schizophrenia
Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia
The Synergistic Effect of Hypoglycemic Index Diet on Refractory Schizophrenia
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
Deep Brain Stimulation in Treatment Resistant Schizophrenia
Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia
Occupational Therapy in the Rehabilitation of Executive Functions in Patients With Schizophrenia
Repetitive Transcranial Magnetic Stimulation for Refractory Auditory Hallucinations in Schizophrenia